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Clinical Inertia in the Management of
Low-Density Lipoprotein Abnormalities
in an HIV Clinic
James H. Willig,1 David A. Jackson,1 Andrew O. Westfall,3
Jeroan Allison,2 Pei-Wen Chang,1 James Raper,1 Michael S. Saag,1
and Michael J. Mugavero1
Divisions of 1Infectious Diseases and 2General Internal Medicine, Department
of Medicine, and 3Department of Biostatistics, University of Alabama at
Birmingham, Birmingham
A retrospective cohort study evaluating the frequency of and
factors related to clinical inertia in low-density lipoprotein
(LDL) management was performed. Subjects were 90 patients
that were not meeting National Cholesterol Education Pro-
gram Adult Treatment Panel III LDL goals at the University
of Alabama at Birmingham 1917 HIV/AIDS Clinic between
1 August 2004 and 1 August 2005. Clinical inertia was ob-
served in 44% of cases. Patients with higher baseline LDL
levels were less likely to experience inertia, whereas women
and those in the highest coronary heart disease risk category
were more likely to be affected.
HAART has revolutionized HIV care, transforming a uniformly
lethal illness into a chronically managed condition in popu-
lations with access to treatment. The success of HAART has
resulted in new challenges in HIV-related morbidity and mor-
tality, including a high prevalence of cardiovascular risk factors
and coronary artery disease [1, 2]. Dyslipidemias are important
cardiovascular risk factors among HIV-infected patients, be-
cause both the disease and antiretroviral therapy contribute to
lipid abnormalities [3, 4]. During outpatient clinic encounters,
contemporary HIV providers must now increasingly treat dys-
lipidemias and other chronic comorbid medical conditions in
addition to managing HIV infection with antiretroviral and
associated medications (e.g., prophylactic medications).
In non-HIV primary care settings, clinical inertia, defined
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as failure to initiate or intensify therapy when indicated on the
basis of evidence-based guidelines, has been recognized as a
common problem that presents an important barrier in the
successful management of dyslipidemias and other chronic dis-
orders [5, 6]. The role of clinical inertia in the management
of lipid abnormalities in HIV-infected populations has not yet
been studied. Therefore, we investigated the prevalence of clin-
ical inertia and the factors associated with its occurrence among
dyslipidemic HIV-infected patients in our outpatient HIV
cohort.
Methods. The University of Alabama at Birmingham
(UAB) 1917 HIV/AIDS Clinic Cohort Observational Database
Project is a prospective cohort study that contains detailed
sociodemographic, psychosocial, and clinical information from
clinic patients, including 11500 patients who are currently re-
ceiving care. The clinic uses a locally programmed electronic
medical record that imports all laboratory values from the cen-
tral UAB laboratory, requires electronic prescription for all
medications, and contains detailed encounter notes. This ret-
rospective cohort study was approved by the UAB Institutional
Review Board.
For this analysis, patients with an initial lipid panel per-
formed during July–December 2004 (LDL1), a second lipid
panel 12 weeks to 9 months later (LDL2), and a final lipid
panel 123 months after the first (LDL3) were identified in
our database. Individual low-density lipoprotein (LDL) goals
were calculated for each patient meeting these criteria on the
basis of the third report of the National Cholesterol Education
Program Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults executive summary
(NCEP-ATP III) [7]. LDL levels were directly measured, not
calculated, at our reference laboratory. Patients with the fol-
lowing profiles were included in the analysis; (1) patients who
did not meet their LDL goal at LDL1 and LDL2 measurements,
and (2) patients with abnormal results at LDL1 who met their
LDL goal at the LDL2 measurement because of a pharmaco-
logical intervention initiated after the LDL1 measurement.
Patients who met their NCEP-ATP III LDL goal at their LDL2
measurement in the absence of pharmacological interventions
were excluded. This criterion was used to avoid the misclas-
sification of clinical inertia for patients with isolated elevations
in their LDL level for whom pharmacological intervention was
not indicated or those who responded to lifestyle modification
alone.
Clinical inertia was recorded as a dichotomous variable, de-
fined as failure to initiate an appropriate pharmacological LDL-
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lowering intervention (including fish oil, 3-hydroxy-3-meth-
ylglutaryl coenzyme A [HMG-CoA] reductase inhibitors,
ezetimibe, or niacin) or failure to refer to another provider for
lipid management during the 12-month study period for a
patient with a persistently abnormal LDL level. Pharmacological
interventions included recommendation, initiation, dose es-
calation, or change to a more potent lipid-lowering agent or
the addition of a second LDL-lowering drug; adherence coun-
seling directed at lipid therapy; or a change in HAART in re-
sponse to an LDL abnormality. Interventions were determined
by detailed review of all provider notes and medications pre-
scribed during the study period. When rationale for avoidance
of pharmacological interventions addressing LDL abnormalities
was included in provider notes (e.g., past toxicity to HMG-
CoA reductase inhibitor or interaction with concurrent med-
ications), the encounter was exonerated from being classified
as clinical inertia.
After a 12-week trial of therapeutic lifestyle changes, guide-
lines recommend the initiation of lipid-lowering drug therapy
if LDL goals are not achieved [7]. Study inclusion criteria re-
quiring a second lipid measurement (LDL2) at least 12 weeks
after the first (LDL1) ensured that all study patients both had
an adequate time period to respond to lifestyle changes and
met criteria for advancement to pharmacological LDL-lowering
interventions.
Analytically, univariate logistic regression analyses were per-
formed to evaluate the relationship between clinical inertia and
a priori–selected independent variables. Next, a multivariable
logistic regression model was used to evaluate factors associated
with clinical inertia while adjusting for covariates. Variable se-
lection for the multivariable model was based on univariate
results and clinical judgment. All analyses were performed using
SAS software, version 9.1.3 (SAS Institute).
Results. A total of 640 patients had lipid panels performed
during July–December 2004 (LDL1) and again 12 months later
(LDL3). Of these, 138 patients (22%) did not meet their NCEP-
ATP III LDL goal at their LDL1 measurement. Ninety (65%)
of the 138 patients met study inclusion criteria; 10 were ex-
cluded because they lacked an intermediate LDL (LDL2) mea-
surement, and 38 were excluded because they achieved their
LDL goal in subsequent lipid measurements (LDL2) in the
absence of pharmacological intervention or in response to life-
style modification alone. Demographic and medical character-
istics of study participants included the following: median age,
46 years; white race, 61%; and male sex, 80%. Fifty-two percent
were men who have sex with men, 36% were heterosexual, 47%
received protease inhibitors during the observation period, 46%
were active smokers, and 30% were known to have diabetes
(table 1). Clinical inertia in lipid management was observed
for 40 (44%) of 90 patients during a median observation time
of 365 days. No pharmacological interventions occurred for
these patients despite persistently abnormal LDL values over a
median of 4 visits (interquartile range, 3–4 visits) and 4.5 LDL
measurements (interquartile range, 4–5 LDL measurements).
In multivariable logistic regression analysis, patients with
baseline LDL elevations greater than their NCEP-ATP III LDL
goal (OR, 0.56 per 20 mg/dL; 95% CI, 0.32–0.99) and those
belonging to the 2 NCEP-ATP III lower risk categories (0–1
risk factor with LDL goal of !130 mg/dL or 2 risk factors
with LDL goal of !160 mg/dL) for cardiovascular disease (OR,
0.32; 95% CI, 0.10–0.99) were less likely to experience clinical
inertia. Female patients had an increased risk of experiencing
clinical inertia (OR, 6.59; 95% CI, 1.54–28.2). Baseline liver
function tests (measurements of serum aspartate and alanine
aminotransferase, alkaline phosphatase, indirect and direct bil-
irubin levels) and hepatitis C virus infection status had no
statistically significant association with clinical inertia on uni-
variate analysis (data not shown). No other study variables
achieved statistical significance (table 1).
Discussion. In our cohort, clinical inertia or failure to ini-
tiate or adjust lipid management was observed for 44% of
patients with persistently abnormal LDL levels in our outpatient
cohort, despite a median of 4 clinical visits during a 12-month
study period. Although clinical inertia in lipid management has
been well studied in other patient populations, this is the first
study, to our knowledge, to evaluate clinical inertia in HIV-
infected patients. Previous studies of non–HIV-infected persons
have documented rates of provider intensification of phar-
macotherapy for elevated lipids in 16%–56% of provider visits
[8, 9]. Because patients with HIV infection are living longer
and becoming increasingly affected by dyslipidemia and other
cardiovascular risk factors, this area of research is critical for
improving long-term clinical outcomes.
In our study, lipid abnormalities in patients further from
their NCEP-ATP III LDL goal at baseline were more aggressively
managed—that is, these patients were significantly less likely
to experience clinical inertia. However, patients in the highest
risk category (LDL level goal, !100 mg/dL) for cardiovascular
disease were more likely to experience inertia in their lipid
management. This may relate to providers focusing more on
absolute LDL levels than on individualized LDL goals (e.g.,
!100 , !130, or !160 mg/dL) based on coronary heart disease
risk category as defined by the NCEP-ATP III guidelines.
Consistent with studies of non–HIV-infected patients [10],
women were disproportionately affected by clinical inertia. Sex
bias in provider attitudes ascribing greater importance to con-
trol of cardiovascular disease risk factors among men has been
reported in other patient populations [11]. Further sex dis-
parities in the care of HIV-infected women have been docu-
mented, including lower rates of HAART initiation and use of
prophylaxis against opportunistic infections [12]. Understand-
ing the underlying causes of clinical inertia and therapeutic sex
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Table 1. Characteristics of 90 HIV-infected patients with initial LDL levels above NCEP-ATP III goals at the University
of Alabama at Birmingham 1917 HIV/AIDS Clinic from August 2004 to August 2005.
Characteristic
Overall
(n p 90)
Inertia OR (95% CI)
No
(n p 50)
Yes
(n p 40) Crude Adjusted
Age,a years 46.0 (40.3–52.7) 45.5 (40.0–49.5) 47.3 (41.7–56.2) 1.72b (1.07–2.79) 1.65b (0.95–2.85)
Sex
Female 18 (20) 6 (12.0) 12 (30.0) 3.14 (1.06–9.33) 6.59 (1.54–28.2)
Male 72 (80) 44 (88.0) 28 (70.0) R R
Race
African American 35 (38.9) 16 (32.0) 19 (47.5) 1.92 (0.81–4.54) 0.70 (0.22–2.21)
White 55 (61.1) 34 (68.0) 21 (52.5) R R
Body mass indexa 26.1 (23.9–30.2) 27.0 (23.1–30.2) 25.4 (24.1–30.5) 1.02 (0.96–1.08) …
Protease inhibitor usec
Yes 42 (46.7) 26 (52.0) 16 (40.0) 0.62 (0.27–1.43) 0.54 (0.20–1.45)
No 48 (53.3) 24 (48.0) 24 (60.0) R R
Active smokingc
Yes 41 (45.6) 23 (46.0) 18 (45.0) 0.96 (0.42–2.21) …
No 49 (54.4) 27 (54.0) 22 (55.0) R …
Diabetes mellitus
Yes 27 (30.0) 15 (30.0) 12 (30.0) 1.00 (0.40–2.48) …
No 63 (70.0) 35 (70.0) 28 (70.0) R …
CD4 cell count,a cells/mm3 457 (267–616) 520 (281–662) 389 (220–547) 0.94d (0.86–1.02) 0.91d (0.82–1.01)
Plasma HIV load,a 1og10 copies/mL 1.69 (1.69–2.86) 1.69 (1.69–2.10) 2.00 (1.69–3.47) 1.07 (0.96–1.18)
e …
CHD
Yes 7 (7.8) 2 (4.00) 5 (12.5) 3.43 (0.63–18.7) …
No 83 (92.2) 48 (96.0) 35 (87.5) R …
No. of visitsf 4.00 (3.00–4.00) 4.00 (3.00–4.00) 4.00 (3.00–4.50) 0.95 (0.73–1.26) …
No. of LDL measurements 4.50 (4.00–5.00) 5.00 (4.00–5.00) 4.00 (4.00–5.00) 1.01 (0.75–1.35) …
NCEP-ATP III LDL cholesterol goal, mg/dL
!100 (CHD and CHD risk equivalents) 43 (47.8) 21 (42.0) 22 (55.0) R R
!130 and !160 (0–1 or 2 risk factors) 47 (52.2) 29 (58.0) 18 (45.0) 0.59 (0.26–1.37) 0.32 (0.10–0.99)
Elevation in LDL above goal,a mg/dL 24.0 (16.0–42.0) 27.5 (19.0–42.0) 21.0 (14.0–37.5) 0.78g (0.53–1.15) 0.56g (0.32–0.99)
Primary provider
MD 32 (35.6) 15 (30.0) 17 (42.5) 1.72 (0.72–4.12) …
Other (PA/CRNP) 58 (64.4) 35 (70.0) 23 (57.5) R …
Lipids managed by outside provider
Yes 18 (20.0) 9 (18.0) 9 (22.5) 1.32 (0.47–3.72) …
No 72 (80.0) 41 (82.0) 31 (77.5) R …
NOTE. Data are no. (%) or median (interquartile range), unless otherwise indicated. CHD, coronary heart disease; CRNP, certified registered
nurse-practitioner; LDL, low-density lipoprotein; MD, medical doctor; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel
III [7]; PA, physician’s assistant; R, reference.
a At time of initial LDL measurement.
b OR per 10 years.
c At any time during 1 year study period.
d OR per 50 cells/mm3.
e OR per 5000 copies/mL.
f Any visit to the UAB 1917 Clinic throughout the year for the purpose of laboratory measurements, sick call, and/or regularly scheduled follow-up.
g OR per 20 mg/dL.
disparities for HIV-infected women are important areas for
future research.
Clinical inertia is believed to result from a combination of
patient, system, and provider factors. Patient factors include
low health literacy, polypharmacy, adverse effects of medication,
costs, and denial of having an illness or of its severity. System
factors encompass a lack of decision support and poor com-
munication between physicians and staff. Provider factors in-
clude overestimation of care provided and a lack of awareness
of recommended guidelines [6]. For HIV-infected patients, an
additional factor contributing to clinical inertia may be de-
creased comfort in the management of chronic comorbid med-
ical conditions among infectious disease specialists, compared
with general medicine practitioners [13].
This study has limitations. Because the results were obtained
in a single center, they may not be generalizable to other regions
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of the country or other HIV clinics. This analysis was under-
powered to gauge the impact of clinical inertia on biological
outcomes—namely, achievement of LDL goals. This study fo-
cused on patient factors associated with clinical inertia and did
not assess system and provider factors.
Clinical inertia is a well-chronicled obstacle to achieving suc-
cess in treatment of dyslipidemia in non–HIV-infected popu-
lations. It is not surprising that our study found that clinical
inertia plays an important role in the management of dysli-
pidemia in HIV-infected patients as well; 44% of patients with
persistently elevated LDL levels were not prescribed a phar-
macological intervention during a 12-month study period. Sys-
tems-based interventions to reduce clinical inertia have im-
proved lipid management in other patient populations [8].
Future studies should further evaluate provider and system
factors associated with clinical inertia of lipid management for
HIV-infected patients. Such studies will be vital to the devel-
opment of multilevel interventions that may lead to improved
lipid management and ultimately to reduced cardiovascular
morbidity and mortality for people living with HIV/AIDS.
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